Список литературы

Поставить закладку

1. Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FGFR1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003; 348 (13): 1201-1214.
2. Cross NC, Reiter A. Fibroblast growth factor receptor and platelet-derived growth factor receptor abnormalities in eosinophilic myeloproliferative disorders. Acta Haematol 2008; 119 (4): 199-206.
3. Bain BJ. Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB or FGFR1. Haematologica 2010; 95 (5): 696-698.
4. Klion AD. Eosinophilic Myeloproliferative Disorders. ASH Education Book, December 10, 2011 vol. 2011 (no. 1): 257-263.
5. Havelange V, Demoulin J-B. Review of current classification, molecular alterations, and tyrosine kinase inhibitor therapies in myeloproliferative disorders with eosinophilia. Journal of Blood Medicine 2013; 4: 111-121.
6. Baccarani M, Cilloni D, Rondoni M, et al. The efficacy of imatinib mesylate in patients with hypereosinophilic syndrome. Results of a multicenter prospective study. Haematologica 2007; 92 (9): 1173-1179.
7. Gotlib J, Cools J. Five years since the discovery of FIP1L1-PDGFRA: what we have learned about the fusion and other molecularly defined eosinophilias. Leukemia 2008; 22 (11): 19992010.
8. Jackson CC, Medeiros LJ, Miranda RN. 8p11 myeloproliferative syndrome: a review. Hum Pathol 2010; Apr; 41 (4): 461-476.
9. Chase A, Bryant C, Score J, and Cross N.C.P. Ponatinib as a targeted therapy for FGFR1 fusions associated with the 8p11 myeloproliferative syndrome. Haematologica 2013; January; 98 (1): 103-106.
10. Reiter A, Walz C, Watmore A et al. The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2. Cancer Res 2005; 65:2662-2667.
11. Bain BJ, Ahmad S. Should myeloid and lymphoid neoplasms with PCM1-JAK2 and other rearrangements of JAK2 be recognized as specific entities? Br J Haematol 2014; 166:809-817.
12. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016; 127: 2391-2405.
13. NMPN Study Group. Guidelines for the diagnosis and treatment of eosinophilia. 2nd version, September 2012, www.nordicmpd.org.:4.
14. Muller AM, Martens UM, Hofmann SC, et al. Imatinib mesylate as a novel treatment option for hypereosinophilic syndrome: two case reports and a comprehensive review of the literature. Ann Hematol 2006; 85: 1-16.
15. Gotlieb J. World Health Organization-defined eosinophilic disorders: 2014 update on diagnosis, risk stratification, and management. Am J Hematol 2014; 89: 325-337.
16. Gleich GJ, Lieferman KM, Pardanani A, et al. Treatment of hypereosinophilic syndrome with imatinib mesylate. Lancet 2002; 359: 1577-1578.
17. Klion AD, Robyn J, Akin C, et al. Molecular remission and reversal of myelofibrosis is response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome. Blood 2004; 103: 473-478.
18. Pardanani A, Reeder T, Porrata LF, et al. Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. Blood 2003; 101: 3391-3397.
19. David M, Cross NC, Burgstaller S, et al. Durable responses to imatinib in patients with PDGFRB fusion-gene positive and BCR-ABL-negative chronic myeloproliferative disorders. Blood 2007; 109: 61-64.
20. Немченко И.С., Хорошко Н.Д., Туркина А.Г. с соавт. FIPlLl-PDGFRa-позитивное миелопролиферативное заболевание с гиперэозинофилией: клиническая характеристика и возможности патогенетической терапии. Тер. архив 2005; №7: с. 90-92.
21. Bochner BS, Gleich GJ. What targeting eosinophils has taught us about their role in disease. J Allergy Clin Immunol 2010; 126: 16-25.
22. Klion AD. How I treat hypereosinophilic syndromes. Blood 2009; 114: 3736-3741.
23. Tefferi A, Gotlib J, Pardanani A. Hypereosinophilic syndrome and clonal eosinophilia: Point of care diagnostic algorithm and treatment update. Mayo Clin Proc 2010; 85: 158-164.
24. Fruehauf S., Fiehn C., Haas R., Doehner H., Hunstein W. Sustained remission of idiopathic hypereosinophilic syndrome following alpha-interferon therapy. Acta Haematol1993; 89 (2):91-3.
25. Bockenstedt PL., Santinga JT., Bolling SF. Alpha-Interferon treatment for idiopathic hypereosinophilic syndrome. Am J Hematol 1994 Mar; 45 (3): 248-51. 24. Butterfield JH. Interferon treatment for hypereosinophilic syndromes and systemic mastocytosis. Acta Haematol 2005; 114 (1): 26-40.
26. Sakamoto K, Erdreich-Epstein A, de Clerck Y, et al. Prolonged clinical response to vincristine treatment in two patients with hypereosinophilic syndrome. Am J Pediatr Hematol Oncol 1992; 14: 348-351.
27. Jabbour E, Verstovsek S, Giles F, et al. 2-chlorodeoxyadenosine and cytarabine combination therapy for idiopathic hypereosinophilic syndrome. Cancer 2005; 104: 541-546.
28. Хорошко Н.Д., Мокеева Р.А., Туркина А.Г. с соавт. Идиопатический и симптоматический гиперэозинофильные синдромы (сравнительная характеристика на основе 14 наблюдений). Тер. архив. 1997; №7; с. 26-33.
29. Хорошко Н.Д., Мокеева Р.А., Сысоева Е.П. с соавт. Бластный криз в исходе миелопролиферативного варианта идиопатического гиперэозинофильного синдрома. Гематол. и трансфузиол. 2000; т.45, №2; с. 37-42.
30. Rumi E., Milosevic JD, Selleslag D, et al. Efficacy of ruxolitinib in myeloid neoplasms with PCM1-JAK2 fusion gene. Ann Hematol 2015; 94 (11): 1927-1928.
31. Оксфордский центр доказательной медицины. Уровни доказательности (Май 2001). Разработали Боб Филипс К.Б., Дейв Сакетт, Доуг Баденох, Шарон Штраус, Брайен Хайнес, Мартин Давес в ноябре 1998.